A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)

Inclusion Criteria: * Pre-menopausal female 21-38 years of age at screening * History of repeated IVF failures despite transfer of good-quality embryos, defined as follows: * ...1) 3 or more IVF cycles involving transfer of at least two good-quality cleavage-stage embryos or at least one good-quality blastocyst (2010 SART (Society for Assisted Reproductive Technologies) grading criteria)that resulted in one of the following outcomes: * \* .....a) no pregnancy * \* .....b) biochemical pregnancy * \* .....c) spontaneous abortion of an intrauterine clinical pregnancy before or equal to completed Week 8 of gestation * ...2) At least two of the eligible IVF failures must have involved transfer of fresh embryos * ...3) At least two of the eligible IVF failures must have involved retrieval of at least 5 oocytes * ...4) No live birth, abortion later than Week 8 of gestation, or stillbirth may have occurred since the first of these IVF failures * Body mass index (BMI) of 19-38 kg per m2 at screening * TSH (thyroid-stimulating hormone) less than or equal to 4.0 mIU/L(milli-International units per Liter) for subjects with no history of hypothyroidism, or TSH less than or equal to 2.5 mIU/L for subjects with a history of hypothyroidism, at screening Exclusion Criteria: * Prior diagnosis of moderate or severe ovarian hyperstimulation syndrome (OHSS) * Clinically confirmed polycystic ovary syndrome (PCOS) * History of a major congenital anomaly in the subject, her current male partner, or first degree relative of either the subject or her current male partner * Known karyotype abnormalities in either the subject or her current male partner / sperm donor * Any prior pregnancy terminated for a fetal medical condition * History of severe (stage IV) endometriosis * Current or past systemic autoimmune disease * Any uncontrolled clinically significant medical condition (e.g. asthma, Type II diabetes, infection)